BioLife Solutions Bundle
Who Owns BioLife Solutions?
Understanding a company's ownership is key in the life sciences sector. BioLife Solutions, Inc. (NASDAQ: BLFS) saw significant investor interest with its July 2020 public offering, raising about $86 million.
Originally incorporated in Delaware in 1998 as a subsidiary of Cryomedical Sciences, Inc., the company's journey began in 1987 as Trans Time Medical Products, Inc., focusing on biopreservation media.
The company is a key player in the cell and gene therapy market, offering essential bioproduction products and services. As of July 21, 2025, its market capitalization stood at approximately $993 million, with 47.6 million shares outstanding. This growth reflects its expanding role and investor confidence in its innovative solutions, including its widely used BioLife Solutions PESTEL Analysis.
Who Founded BioLife Solutions?
The origins of BioLife Solutions' ownership trace back to Cryomedical Sciences, Inc., a company initially focused on cryosurgical products. BioLife Solutions was established in 1998 as an academic incubator subsidiary of Cryomedical Sciences, Inc. This foundational period laid the groundwork for the company's future in biopreservation technologies.
| Year | Event | Parent Company | Ticker |
|---|---|---|---|
| 1998 | Formation as an academic incubator subsidiary | Cryomedical Sciences, Inc. | N/A |
| 2002 (May) | Restructuring and recapitalization | Cryomedical Sciences, Inc. | N/A |
| 2002 (September) | Name change to BioLife Solutions, Inc. and public trading | N/A | BLFS (OTCBB) |
Early Development Focus
The company's early efforts were concentrated on developing cryopreservation media. This focus stemmed from Cryomedical Sciences' initial work in cryosurgery technology, initiated in 1992.
Key Scientific Contributions
Scientific minds were integral to BioLife's early technological advancements. These individuals contributed to understanding cell death in relation to temperature changes.
Foundational Leadership
Dr. Mathew played a significant role in the company's initial manufacturing and quality systems. His expertise was crucial in establishing the operational framework for BioLife Solutions.
Corporate Transformation
A significant restructuring in May 2002 marked a pivotal moment. This strategic shift aimed to reposition the company to better serve the evolving needs of the biotech market.
Public Market Entry
By September 2002, the company officially became BioLife Solutions, Inc. and began trading on the OTCBB under the ticker symbol 'BLFS'. This marked its transition to a publicly traded entity.
Early Ownership Details
Specific details regarding early individual equity splits or exact shareholdings of the initial founders are not extensively documented in recent public filings. The initial ownership structure was intrinsically linked to its parent company at the time.
The initial foundation of BioLife Solutions was built upon the cryopreservation technology developed by Cryomedical Sciences, Inc. While precise early ownership percentages are not publicly detailed, the company's trajectory indicates a strategic spin-off and rebranding to focus on the biopreservation market. Understanding the Target Market of BioLife Solutions is key to appreciating its early strategic direction.
Key Aspects of BioLife Solutions' Founding
The company's inception and early development were closely tied to its parent organization's expertise. This provided a strong scientific and operational base for its specialized market focus.
- Formed in 1998 as a subsidiary of Cryomedical Sciences, Inc.
- Focused on cryopreservation media development.
- Underwent restructuring and rebranding in 2002.
- Began public trading as BioLife Solutions, Inc. (BLFS) in September 2002.
BioLife Solutions SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has BioLife Solutions’s Ownership Changed Over Time?
BioLife Solutions, Inc. became a publicly traded entity, with its shares available on the NASDAQ Global Market under the ticker BLFS. A significant capital infusion occurred in July 2020 through a public offering that sold 5,951,250 shares of common stock at $14.50 each, generating approximately $86 million.
| Metric | Value (as of July 21, 2025) |
| Market Capitalization | Approximately $993 million |
| Shares Outstanding | 47.6 million |
As of July 2025, institutional investors are the dominant force in BioLife Solutions ownership, holding an impressive 93.24% of the company's shares. Fintel data from July 21, 2025, indicates that 444 institutional owners and shareholders collectively possess 63,742,247 shares. Key institutional stakeholders include Casdin Capital, LLC, BlackRock, Inc., Invesco Ltd., Vanguard Group Inc., Fred Alger Management, Llc, and State Street Corp. Notably, Casdin Partners Master Fund, L, a significant shareholder, reduced its direct holdings by selling 1,000,000 shares in June 2025, leaving them with 7,707,165 shares, valued at roughly $183.43 million.
Understanding BioLife Solutions' Shareholder Landscape
The ownership structure of BioLife Solutions is heavily weighted towards institutional investors, influencing company direction. Understanding these major stakeholders is key to grasping the company's strategic trajectory.
- Institutional investors hold over 93% of shares as of July 2025.
- Mutual funds represent 47.81% of shareholder types as of March 2025.
- Foreign institutions account for 5.12% of ownership.
- Insider ownership stands at 1.85% as of July 2025.
- The company is publicly traded on the NASDAQ Global Market.
Delving deeper into the shareholder breakdown as of March 2025, mutual funds are the largest category, controlling 47.81% of the shares. Foreign institutions hold a smaller but notable portion at 5.12%. Insider ownership, representing individuals within the company, was reported at 1.85% as of July 22, 2025, with no reported holdings by promoters. This concentration of ownership among large funds and asset managers suggests that the company's strategic decisions and governance are significantly shaped by the investment mandates of these entities, as further explored in the Marketing Strategy of BioLife Solutions.
BioLife Solutions PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on BioLife Solutions’s Board?
The strategic direction and operational management of BioLife Solutions are guided by its executive leadership team and Board of Directors. As of December 16, 2024, the board membership increased to six with the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation, effective January 2, 2025.
| Board Member | Role | Key Experience |
|---|---|---|
| Roderick de Greef | Chairman and Chief Executive Officer | Over 20 years with BioLife, former CFO and COO, board member 2000-2013 |
| Tony J. Hunt | Director (effective Jan 2, 2025) | Executive Chairman of Repligen Corporation |
| Cathy Coste | Independent Director, Chairman of the Audit Committee | Over 30 years in financial oversight and corporate governance |
| Joydeep Goswami | Director | Chief Strategy and Corporate Development Officer at Illumina |
The company operates under a standard one-share-one-vote structure, common for companies listed on NASDAQ. With over 93% institutional ownership, the majority of voting power is concentrated among these large shareholders, who typically play a significant role in board elections and corporate governance decisions. This substantial institutional backing highlights the confidence of major investors in the company's trajectory and its Revenue Streams & Business Model of BioLife Solutions.
Understanding BioLife Solutions' Governance
The Board of Directors and executive team are pivotal in steering BioLife Solutions. Their collective experience shapes the company's strategic path.
- Roderick de Greef leads as Chairman and CEO.
- Tony J. Hunt will join the board in early 2025.
- Cathy Coste provides extensive financial oversight.
- Joydeep Goswami brings valuable industry expertise.
- Voting power is largely held by institutional investors.
BioLife Solutions Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped BioLife Solutions’s Ownership Landscape?
Over the last few years, BioLife Solutions has significantly adjusted its ownership structure and strategic direction through a series of divestitures and acquisitions. These actions reflect a deliberate move to concentrate on higher-margin, proprietary offerings within the cell processing sector.
| Transaction | Date | Acquired For | Sold For |
|---|---|---|---|
| SciSafe Holdings, Inc. (wholly-owned subsidiary) | November 2024 | $39 million (October 2020) | $73 million (cash) |
| Global Cooling, Inc. (subsidiary) | April 2024 | N/A | N/A |
| Arctic Solutions, Inc. (subsidiary) | November 2024 | N/A | N/A |
| PanTHERA CryoSolutions (90% stake) | April 2025 | N/A | N/A |
These strategic maneuvers are designed to refine the company's portfolio and bolster its financial standing, evidenced by a cash position of $109.2 million as of March 2025. The company's forward-looking revenue guidance for 2025 is between $95.5 million and $99.0 million, indicating a projected growth of 16% to 20% over 2024, with a pronounced emphasis on its Cell Processing platform. This strategic focus suggests potential for further shifts in ownership as the company progresses.
Institutional Investor Dominance
Institutional investors now hold over 93% of BioLife Solutions' stock as of July 2025. This high level of institutional ownership underscores confidence in the company's strategic direction and future prospects.
Insider Trading Activity
Recent insider transactions include sales by major shareholders like Casdin Partners Master Fund, L, which divested 1,000,000 shares in June 2025. The Chief Technology Officer also sold 1,115 shares in July 2025, primarily for tax withholding obligations.
Strategic Portfolio Realignment
The divestiture of subsidiaries like SciSafe Holdings, Inc., Global Cooling, Inc., and Arctic Solutions, Inc. signifies a strategic pivot. The company is concentrating its efforts on its core, high-margin cell processing consumable solutions.
Acquisition for Growth
The acquisition of a 90% stake in PanTHERA CryoSolutions in April 2025 further strengthens BioLife Solutions' position in the bioproduction consumables market. This move aligns with the company's Growth Strategy of BioLife Solutions.
BioLife Solutions Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of BioLife Solutions Company?
- What is Competitive Landscape of BioLife Solutions Company?
- What is Growth Strategy and Future Prospects of BioLife Solutions Company?
- How Does BioLife Solutions Company Work?
- What is Sales and Marketing Strategy of BioLife Solutions Company?
- What are Mission Vision & Core Values of BioLife Solutions Company?
- What is Customer Demographics and Target Market of BioLife Solutions Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.